Taiwan cancer drugs developer seeks Hong Kong bond issue ahead of IPO after delisting from Taipei

JHL Biotech, a Taiwan developer of cheaper alternatives to patent-protected biological drugs, has raised US$106 million from a convertible bond issue, ahead of its planned Hong Kong initial public offering (IPO) aiming to raise some US$250 million.
( read original story …)


Related Post

Walter Kwok, Hong Kong Developer Who Survived Kidn...
views 10
HONG KONG — Walter Kwok, a Hong Kong property tyco...
Hong Kong utility CLP eyes twofold growth and IPO ...
views 9
there is an ambitious business plan where both par...
ENTREVESTOR: Adaptiiv finds major clients in Hong ...
views 9
The university in Hong Kong will use 3D Bolus in r...
Hong Kong: HANG SENG INDEX (.HSI) lingering concer...
views 16
South Korea’s Kospi gained 0.25 percent to close a...
AXA and HSBC launch new plan
views 20
AXA Hong Kong has collaborated with the Hongkong a...
World’s longest sea bridge opens between Mac...
views 22
“This is part of the ‘Greater Bay Area’ Project, w...
Will Chinese Firms Succeed in Hong Kong?
views 23
“The Hong Kong IPO market is about to see signific...
‘Eternal vigilance’ needed in Hong Kong to uphold ...
views 21
A distinguished Hong Kong judge who has ruled on s...
Hong Kong-Zhuhai-Macau bridge offers opportunities...
views 21
Hong Kong’s trade and logistics sectors are raring...
‘World’s longest sea bridge between Ho...
views 25
A $20-billion bridge connecting Hong Kong and Maca...